Sandeep H. Kiri

Slough, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Long-term efficacy of biologics in moderate-to-severe hidradenitis suppurativa: A systematic review and MAIC.

Long-term efficacy of biologics in moderate-to-severe hidradenitis suppurativa: A systematic review and MAIC.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: October 02, 2025

Short-term efficacy of biologics in moderate-to-severe hidradenitis suppurativa: A systematic review and NMA.

Short-term efficacy of biologics in moderate-to-severe hidradenitis suppurativa: A systematic review and NMA.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: March 13, 2025

Economic burden of hidradenitis suppurativa based on healthcare resource utilization: German claims data analysis.

Economic burden of hidradenitis suppurativa based on healthcare resource utilization: German claims data analysis.

Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Published: October 10, 2024

Long-Term Efficacy and Safety of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: Updated Systematic Literature Review and Network Meta-analysis.

Long-Term Efficacy and Safety of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: Updated Systematic Literature Review and Network Meta-analysis.

Journal: Dermatology and therapy

Published: September 24, 2024

Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons.

Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons.

Journal: Rheumatology and therapy

Published: October 06, 2022

Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis.

Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis.

Journal: Dermatology and therapy

Published: May 16, 2022

Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis.

Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis.

Journal: Therapeutic advances in musculoskeletal disease

Published: April 29, 2022

Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis.

Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis.

Journal: Dermatology and therapy

Published: July 22, 2021

Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK.

Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK.

Journal: PharmacoEconomics - open

Published: March 14, 2020

Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis.

Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis.

Journal: RMD open

Published: October 01, 2019

Predicting disease progression and poor outcomes in patients with moderately active rheumatoid arthritis: a systematic review.

Predicting disease progression and poor outcomes in patients with moderately active rheumatoid arthritis: a systematic review.

Journal: Rheumatology advances in practice

Published: September 21, 2018

Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.

Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.

Journal: Journal of medical economics

Published: June 07, 2018

Showing 1-12 of 14

Last Updated: 09/26/2026